<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276937</url>
  </required_header>
  <id_info>
    <org_study_id>CTR-001</org_study_id>
    <secondary_id>UMIN000014926</secondary_id>
    <nct_id>NCT02276937</nct_id>
  </id_info>
  <brief_title>Randomized Phase IIb Trial of DVC1-0101</brief_title>
  <official_title>DVC1-0101 for Intermittent Claudication Secondary to Peripheral Artery Disease: a Randomized Phase IIb Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyushu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Japan Agency for Medical Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyushu University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DVC1-0101 is a gene therapy medicine to treat peripheral arterial disease (PAD) based on&#xD;
      recombinant F-gene-deleted, non-transmissible Sendai virus (rSeV/dF) expressing human&#xD;
      fibroblast growth factor-2 (FGF-2) gene.&#xD;
&#xD;
      The primary objective of the current Phase IIb study is to investigate the clinical efficacy&#xD;
      of DVC1-0101 (1x10^9 ciu/leg, 5x10^9 ciu/leg) in patients with IC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DVC1-0101 is a gene therapy medicine to treat peripheral arterial disease (PAD) based on&#xD;
      recombinant F-gene-deleted, non-transmissible Sendai virus (rSeV/dF) expressing human&#xD;
      fibroblast growth factor-2 (FGF-2) gene. The previous Phase I/IIa study demonstrated no&#xD;
      serious adverse event related to the administration, and suggested possible improvement of&#xD;
      local blood flow and walking performance of PAD patients.&#xD;
&#xD;
      The primary objective of the current Phase IIb study is to investigate the clinical efficacy&#xD;
      of DVC1-0101 (1x10^9 ciu/leg, 5x10^9 ciu/leg) in patients with IC. We also aim to examine the&#xD;
      dose-response relationship using the rate of improvement in walking function as an indicator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Walking performance assessed by treadmill utilizing Gardner's method</measure>
    <time_frame>6 months</time_frame>
    <description>Change rate from baseline in absolute claudication distance (%ACD) at 6 months Change of ACD from baseline at 6 months Change of peak walking time from baseline at 6 months Change of initial claudication distance (ICD) from baseline at 6 months Change of claudication onset time from baseline at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIRS measurement</measure>
    <time_frame>Pre, day 14, 1, 2, 3, 4, 5, and 6 months</time_frame>
    <description>Measurement of oxygen dynamics in the leg muscles by near infrared spectroscopy after a treadmill</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readministration</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of subjects in whom readministration was not required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WIQ</measure>
    <time_frame>Pre, 1, 3, and 6 months</time_frame>
    <description>Evaluation of QOL based on the Walking Impairment Questionnaire (WIQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical stage classifications</measure>
    <time_frame>Pre, day 14, 1, 2, 3, 4, 5, and 6 months</time_frame>
    <description>Time-course changes using clinical stage classifications (Fontaine classification, Rutherford classification)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABI/TBI</measure>
    <time_frame>Pre, day 14, 1, 3, and 6 months</time_frame>
    <description>Ankle-brachial pressure index/ Toe-brachial pressure index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS</measure>
    <time_frame>Pre, day 1, 2, 3, 5, 7, 14 and monthly until 6 months</time_frame>
    <description>visual analogue scale (VAS) and pain at rest evaluated by the frequency of analgesic use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>Monthly until 1 year after gene transfer</time_frame>
    <description>Incidence of cardiovascular events (to be followed up to 5 years after administration)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Intermittent Claudication</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Placebo (0 ciu/limb)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DVC1-0101 low dose (1x10^9 ciu/limb)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DVC1-0101 high dose (5x10^9 ciu/limb)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DVC1-0101</intervention_name>
    <description>The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.</description>
    <arm_group_label>DVC1-0101 high dose (5x10^9 ciu/limb)</arm_group_label>
    <arm_group_label>DVC1-0101 low dose (1x10^9 ciu/limb)</arm_group_label>
    <arm_group_label>Placebo (0 ciu/limb)</arm_group_label>
    <other_name>rSeV/dF expressing human FGF-2 gene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) Meet criteria (1) to (5) below and are confirmed as such by at least 1 specialist&#xD;
        qualified by the Japanese Society for Cardiovascular Surgery and at least 1 physician with&#xD;
        deep experience Cardiovascular Intervention.&#xD;
&#xD;
          1. arteriosclerosis obliterans with stable symptoms, have intermittent claudication (ACD&#xD;
             &lt; 260 m) and are able to walk on a treadmill&#xD;
&#xD;
          2. resting ankle-brachial pressure index &lt; 0.9&#xD;
&#xD;
          3. refuse revascularization, risk of revascularization may be greater than the benefit,&#xD;
             or develop obliteration after revascularization&#xD;
&#xD;
          4. angiographic findings show patency from the abdominal aorta through to the proximal&#xD;
             side of the external iliac artery&#xD;
&#xD;
          5. angiographic findings meet the above criterion (4), and have stenosis or obliteration&#xD;
             under the femoropopliteal region with morphology defined as type C or D based on&#xD;
             TASCII&#xD;
&#xD;
        2) Administering cilostazol for at least 1 month and still meet criterion 1).&#xD;
&#xD;
        3) Aged 30 and over.&#xD;
&#xD;
        4) Either sex, either inpatients or outpatients.&#xD;
&#xD;
        5) Able to give written consent for themselves.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have ischemic ulcer.&#xD;
&#xD;
          2. Diagnosed with Buerger's disease.&#xD;
&#xD;
          3. Have a current or past history of life-threatening allergies.&#xD;
&#xD;
          4. Have been shown or are suspected to have cancer.&#xD;
&#xD;
          5. With concurrent proliferative intraocular neovascularization.&#xD;
&#xD;
          6. With poorly controlled diabetes mellitus.&#xD;
&#xD;
          7. With concurrent cardiac failure.&#xD;
&#xD;
          8. With untreated severe arrhythmia.&#xD;
&#xD;
          9. Have or are suspected to have interstitial pneumonia.&#xD;
&#xD;
         10. Have progressive hepatic disorders.&#xD;
&#xD;
         11. Have moderate or severe hepatic disorders. (1) aspartate aminotransferase or alanine&#xD;
             aminotransferase &gt;2.5 times the upper limit (2) Prothrombin time is 14 seconds or&#xD;
             longer (3) Serum bilirubin &gt;2.0 times the upper limit&#xD;
&#xD;
         12. Diagnosed with hepatic cirrhosis (classified as B or C on the Child-Pugh).&#xD;
&#xD;
         13. Have an inflammatory disease.&#xD;
&#xD;
         14. Treated with immunosuppressants or corticosteroids for the treatment of various&#xD;
             inflammatory diseases or after organ transplantation.&#xD;
&#xD;
         15. Underwent extirpative surgery of a malignant tumor in the past 5 years.&#xD;
&#xD;
         16. Have had a cerebral hemorrhage or cerebral infarction in the past 6 months.&#xD;
&#xD;
         17. With blood diseases.&#xD;
&#xD;
         18. With moderate or severe renal dysfunction (CCr &lt;40 mL/min)&#xD;
&#xD;
         19. With alcohol or drug dependence.&#xD;
&#xD;
         20. Pregnant/lactating female, or who wish or are suspected to be pregnant.&#xD;
&#xD;
         21. Positive HIV antibodies.&#xD;
&#xD;
         22. Took part in any other clinical studies or research in the past 30 days.&#xD;
&#xD;
         23. Have allergic to the antibiotics and/or the Ribavirin.&#xD;
&#xD;
         24. Not permitted to participate in this study by the principal investigator or&#xD;
             sub-investigator for any other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshikazu Yonemitsu</last_name>
    <role>Study Chair</role>
    <affiliation>Kyushu University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Matsuyama Red-Cross Hospital</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu Central Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>815-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morinomiya Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>536-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Yonemitsu Y, Matsumoto T, Itoh H, Okazaki J, Uchiyama M, Yoshida K, Onimaru M, Onohara T, Inoguchi H, Kyuragi R, Shimokawa M, Ban H, Tanaka M, Inoue M, Shu T, Hasegawa M, Nakanishi Y, Maehara Y. DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14. doi: 10.1038/mt.2012.279. Epub 2013 Jan 15.</citation>
    <PMID>23319060</PMID>
  </reference>
  <reference>
    <citation>Matsumoto T, Tanaka M, Yoshiya K, Yoshiga R, Matsubara Y, Horiuchi-Yoshida K, Yonemitsu Y, Maehara Y. Improved quality of life in patients with no-option critical limb ischemia undergoing gene therapy with DVC1-0101. Sci Rep. 2016 Jul 15;6:30035. doi: 10.1038/srep30035.</citation>
    <PMID>27418463</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyushu University</investigator_affiliation>
    <investigator_full_name>Yoshikazu Yonemitsu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Recombinant Sendai virus</keyword>
  <keyword>fibroblast growth factor-2</keyword>
  <keyword>treadmill</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

